Praxis Precision Medicines Submits Two NDAs for Ulixacaltamide and Relutrigine, Reports Q4/FY25 Results, and Extends Cash Runway into 2028

summarizeSummary

Praxis Precision Medicines announced the submission of two New Drug Applications (NDAs) to the FDA for ulixacaltamide and relutrigine, reported Q4 and full-year 2025 financial results, and confirmed a cash runway extending into 2028.

check_boxKey Events

• Two NDAs Submitted to FDA

  Praxis submitted New Drug Applications (NDAs) for ulixacaltamide in essential tremor (ET) and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), marking a critical step towards commercialization.

• Extended Cash Runway

  The company reported $926.1 million in cash and investments as of December 31, 2025, which, combined with $621.2 million from the January 2026 public offering, is expected to fund operations into 2028.

• Positive Pipeline Progress

  Pre-launch activities for ulixacaltamide and relutrigine are accelerating, and topline results for vormatrigine (FOS) and elsunersen (SCN2A DEE) are anticipated in the first half of 2026.

• Full-Year 2025 Financials

  Praxis reported a net loss of $303.3 million for the full year 2025, with research and development expenses increasing to $267.1 million, reflecting significant investment in its pipeline.

auto_awesomeAnalysis

This 8-K filing signals a significant advancement for Praxis Precision Medicines as it transitions towards becoming a commercial-stage biopharmaceutical company. The submission of two New Drug Applications (NDAs) for ulixacaltamide in essential tremor and relutrigine in DEEs represents a major de-risking event for its pipeline, with pre-launch activities already underway. The robust cash position, bolstered by the recent public offering, provides a substantial runway into 2028, alleviating near-term financing concerns and supporting ongoing R&D and commercialization efforts. Upcoming clinical readouts for vormatrigine and elsunersen in the first half of 2026 will be key catalysts to watch, potentially adding to the company's late-stage pipeline.